Eliot Richard Forster
Eliot Forster[edit]
Eliot Richard Forster is a pharmaceutical / biotechnology professional. He has worked in the UK, US and China in leadership roles in various fields of his industry.[1] [2]
| Eliot Richard Forster | |
|---|---|
 | |
| Born | 27 Feb 1966 Sunderland Tyne & Weir |
| 💼 Occupation | Pharmaceuticals/biotechnology professional |
| 📆 Years active | 1991 - present |
| 👴 👵 Parents |
|
| Family | Howard Neil Forster (brother) |
Personal life[edit]
Eliot has interest in field sports, cricket, jogging, brewing, bee-keeping, poetry and national politics.
Education[edit]
- M.B.A.: Henley Management College (2011)
- Ph.D.: Neurophysiology, University of Liverpool (2001)
- B.Sc. (Hons): Mammalian Physiology, University of Liverpool (1988)
Career[edit]
Eliot began working life as a research associate at Liverpool, his graduate university, in 1991.[3]
In 1993, he moved to Glaxo Wellcome, where he was responsible for the submission and approval of ranitidine bismuth citrate Tritec®, ondansetron Zofran® injectable, and alosetron Lotronex®.[4]
Having worked for 3 years in the Glaxo company, Eliot joined Pfizer Global Research & Development in 1996. From this year through 2007, he worked in several roles - in the UK and the US- and catalyzed the development, trial and approval of several drugs, such as Relpax®, Celebrex®, and Bextra®.[5] He was also involved in supporting the successful submission of Gabapentin for treatment of neuropathic pain in Europe. He implemented a huge re-structuring of clinical research functions in the Drug Development Organisation globally and, in doing so, achieved savings of 10% on the global budget.
Following his work at Pfizer, Forster was appointed as CEO of Solace Pharmaceuticals Inc in 2007, where his small staff discovered and developed treatments for neuropathic pain. For this project, Forster raised 19M USD.
From 2010 until 2015, Forster worked as the CEO of Creabilis SA (dermatological therapies) where he advanced a three-drug portfolio of small molecules and biologics, and raised millions in equity finance.[6]
He joined Immunocore Ltd as CEO in 2015. Over the course of 3 years, he raised a sum of 360M USD through private equity and the Gates Foundation, increasing the shareholder value by more than 15X.[7]
Other roles[edit]
Non-executive directorships[edit]
- Persica Pharmaceuticals Ltd: NED & Co-founder (2013 – to date)
- Spinifex Pty Ltd: NED (2010 – 2015). Sold to Novartis for $700M in Sept. 2015
- Poet in the City: Trustee (2010 – 2015)
- Oxford Biotherapeutics (UK) Ltd: NED (2006 – 2015)
- University of Kent: Council Member (2008 – 2014)
- SabrePharma (UK) Ltd: Co-founder (2008 – 2011)
- Atlantic Healthcare (UK) PLC: NED (2007 – 2010)
- South East Health Technologies Alliance Ltd: NED & Co-founder (2004 – 2007)
Board membershios[edit]
- Advanced Oxford CIC, Founding Chairman (2017 - present)
- Office for the Coordination of Health Research (OSCHR), Board member (2017 - present)
- Life Sciences Industrial Strategy, Board member (2016 - present)
- MedCity Ltd, Founding chairman (2012 - present)
- National Genomics Board, Board member
Other memberships[edit]
Fellow of the Royal Society of Medicine (FRSM), Fellow of the Royal Society of Arts (FRSA), Fellow of the Society of Biology (FSB)
References[edit]
- ↑ Forster, Eliot. "linkedin bio".
- ↑ Forster, Eliot. "Bloomberg bio".
- ↑ forster, eliot. "Avacta profile".
- ↑ Forster, Eliot R.; Palmer, Jonathan L. (2016). "Odansetron article". Annals of Pharmacotherapy. 28 (10): 1203–1204. doi:10.1177/106002809402801022. PMID 7841589.
- ↑ Forster, Eliot. "Eliot Forster appointment at Avacta article".
- ↑ "Eliot Forster appointment at Creabilis, Sofinnova article".
- ↑ forster, eliot (2016-06-05). "Sunday Times article on Eliot Forster's cancer research at Immunocore". The Sunday Times.
Eliot Forster[edit]
Eliot Forster[edit]
This article "Eliot Forster" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Eliot Forster. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
